Summarized by Masters of Longevity from Nature - Main.
A feature article about how a large multiagent AI system was used to replicate a biotech company’s discovery workflow and propose drug-development ideas.
Key Takeaways
- The Virtual Biotech deployed about 37,075 autonomous AI agents to analyse over 55,000 published clinical trials and related datasets.
- Agents identified that drugs targeting proteins active in specific cell types were nearly 50% more likely to reach market.
- The system nominated CD276 as a lung-cancer target and designed an antibody–drug conjugate strategy, subject to human review.
